Welcome to Psychiatric Associates of Southern Connecticut, PC
Our offices are located in Westport, CT and Milford, CT. We provide patients in Southern Connecticut and surrounding areas with the latest in psychiatric treatments, including expert psychopharmacology, Cutting edge therapies, and psychotherapy. We treat patients across the spectrum of psychiatric disorders, and those experiencing problems in living.
Mental Health Treatments Provided
We offer expert diagnostic and psychopharmacological evaluation and consultation, along with ongoing medication treatment. We function as a specialized referral center for other psychiatrists, clinicians, and hospitals for treatment-refractory patients, and utilize advanced techniques (targeted polypharmacy, genetic testing, etc.) for such patients.
We offer individual, group, couples, and family psychotherapy. Our therapists have particular expertise in the areas of psychodynamic psychotherapy, supportive psychotherapy, Cognitive Behavioral Therapy (CBT), Eye Movement Desensitization and Reprogramming (EMDR), Neuro-Linguistic Programming (NLP), and specialized group therapy for TMS patients pre and post treatment, as well as their families.
We also offer the latest evidence based trauma practices of Eye Movement Desensitization & Reprocessing Therapy (EMDR) and Brainspotting (BSP). Our clinic is preparing to offer psychedelic assisted therapy, specifically psilocybin assisted therapy, pending FDA approval for 2025, to treat an array of diagnoses including Post-Traumatic Stress Disorder (PTSD), Obsessive Compulsive Disorder (OCD), Treatment Resistant Depression (TRD), substance abuse, and anxiety disorders.
Mental Health News
Understanding Major Depressive Disorder MDD
The understanding and treatment of Major Depressive Disorder (MDD) is a significant public health issue, not only in the United States but across the world. However, after almost half a century of research, we still do not understand the exact mechanism by which this disorder acts. Twin data show that genetic factors (heritability) only explain
New Work on Psilocybin (Mushrooms) and Depression
Since April, when the New England Journal of Medicine (NEJM) published the paper “Trial of Psilocybin versus Escitalopram for Depression (NEJM, Carhart-Harris et. al, 4/5/21), people with depression are wondering if psilocybin is a good treatment for them. Scientific research on psychedelics has been going on since the 1960s. As the flower children of that
Am I Depressed or Am I Anxious?
Ms. Smith is a new patient who came to see me for a diagnostic evaluation and psychopharmacological treatment. Her presenting complaint was “I have always been an anxious person, but recently my anxiety has been out of control!” Currently this has been the chief complaint I hear in my practice, as pandemic restrictions continue to
COVID-19 Triples Incidence of Depression in the U.S.
Estimates of the incidence of depression in the United States have always been variable, but have hovered around 9-11% prior to COVID-19. After previous national crises, such as 9/11, that rate has almost doubled, before receding again. Now, one year into this pandemic, a recent large-scale investigation has found that the incidence of depression has